COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center.
Erica ParrottaIlya KisterLeigh CharvetCarrie SammarcoValerie SahaRobert Erik CharlsonJonathan HowardJosef Maxwell GutmanMalcolm GottesmanNada Abou-FayssalRobyn WolintzMarshall KeilsonCristina Fernandez-CarbonellLauren B KruppLana Zhovtis RyersonPublished in: Neurology(R) neuroimmunology & neuroinflammation (2020)
Most patients with MS with COVID-19 do not require hospitalization despite being on DMTs. Factors associated with critical illness were similar to the general at-risk patient population. DMT use did not emerge as a predictor of poor COVID-19 outcome in this preliminary sample.